Guided example: rank evidence before naming a family

Return to the adult case. The CBC has anemia with a normal MCV and reticulocytosis, while the smear has polychromasia, target cells, occasional sickle forms, and Howell-Jolly bodies. Those observations support hemolysis or hyposplenic change in context. They do not distinguish HbSS from HbS/beta-zero thalassemia or establish a genotype.

The HPLC S-window fraction is provisional, then capillary electrophoresis finds a major S-zone fraction with no separate C zone. Paired separation methods therefore support a sickling hemoglobin and make a separate C fraction less likely in this specimen. HbA is present, but transfusion 18 days earlier means it cannot be assigned to patient beta-A production. HbF of 12.0% needs medication history because hydroxyurea can raise HbF and mean corpuscular volume.

The defensible ranked interpretation is a transfused HbSS or HbS/beta-zero thalassemia pattern family, with other context-dependent possibilities remaining. The next laboratory action is the local transfusion-aware confirmation pathway, which may include a later specimen, molecular HBB testing, or family studies. Do not release a genotype from this case. When transfusion changes fraction provenance, document the limitation and route the case for policy-directed confirmation.